指南与共识白血病造血干细胞移植与细胞治疗

成人急性淋巴细胞白血病CAR-T细胞输注共识建议:改良德尔菲研究

Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study.
指南 / 共识 · Blood · 2026-01-01

针对成人B细胞急性淋巴细胞白血病(B-ALL)CAR-T细胞治疗的临床实践问题,采用改良德尔菲法,由9名专家组成员初步评估58条建议,经2次会议后34条达成共识,再经27名验证组成员评分,最终33条建议保持共识,涵盖患者选择、桥接治疗、淋巴清除、毒性管理及疗效监测等环节。

要点

  • 9名专家经2次会议从58条建议中达成34条共识,验证后保留33条。
  • 共识涵盖患者选择、桥接与分期、淋巴清除、毒性防治及疗效监测。
  • 推荐涉及CAR-T治疗后巩固/维持治疗的作用,但需结合原文具体条款。

核心结论

  • 改良德尔菲研究形成33条关于成人B-ALL商业CAR-T细胞输注的共识建议。

研究设计与样本

  • 改良德尔菲研究,共识专家组9人,验证组27人,来自ROCCA联盟站点。

主要发现

  • 初始评估58条建议,2次会议后34条达成共识,验证后33条保持共识。

关键数值与推荐

  • 共识主题包括患者选择、桥接与白血病分期、淋巴清除、治疗场所、毒性防治、反应评估与疾病监测及巩固/维持治疗。

临床怎么用

  • 共识建议可用于指导成人B-ALL患者CAR-T细胞治疗的临床实践。

局限性

  • 前瞻性随机试验有限,共识基于专家意见而非高级别证据。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

The use of chimeric antigen receptor (CAR) T-cell therapy is increasing for adult B-cell acute lymphoblastic leukemia (B-ALL), with 3 CD19 CAR T-cell products commercially available. Several key clinical questions related to best practices for CAR T-cell administration in this population exist, and limited prospective randomized trials have been conducted to fill these knowledge gaps. Thus, to help guide clinical practice, we conducted a modified Delphi study to develop and validate consensus recommendations on the administration of commercially available CAR T-cell therapy for adults with B-ALL. Consensus panelists (n = 9) included principal investigators (PIs) from Real World Outcomes Collaborative of CAR T-Cell Therapy in Adult ALL (ROCCA) consortium sites and were selected based on expertise and CAR T-cell center volume. Final panel consensus recommendations were distributed for rating by the remaining PIs from ROCCA consortium sites, which served as the validation group (n = 27). Consensus topics included patient selection, bridging and pre-CAR T-cell leukemia staging, lymphodepletion, and CAR T-cell treatment setting, specific toxicity prevention and management, post-CAR T-cell response assessment and disease monitoring, and the role of consolidation and/or maintenance therapies after CAR T-cell therapy. Initially, 58 recommendation statements were evaluated for consensus. After 2 panel meetings, a total of 34 statements achieved consensus rating among the expert panel. After rating by the validation group, all but 1 recommendation statement continued to meet consensus, for a total of 33 consensus recommendation statements on the administration of CAR T-cell therapy in adult B-ALL.

来源:Blood,查看原文。版权归原作者所有。

引用

  1. Muffly L, Frey NV, Roloff GW, et al. Consensus recommendations for CAR T-cell administration in adult acute lymphoblastic leukemia: a modified Delphi study. Blood. 2026. PMID: 42154904. doi:10.1182/blood.2026033559

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。